Outcome of stem cell transplantation for Waldenström’s macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group

Masatoshi Sakurai, Takehiko Mori, Hitoji Uchiyama, Hiroatsu Ago, Koji Iwato, Tetsuya Eto, Hiromi Iwasaki, Takahito Kawata, Hiroyuki Takamatsu, Satoshi Yamasaki, Minoko Takanashi, Tatsuo Ichinohe, Yoshiko Atsuta, Ritsuro Suzuki

Research output: Contribution to journalArticle

Abstract

The role of stem cell transplantation (SCT) for patients with Waldenström’s macroglobulinemia (WM) remains undetermined. Therefore, we retrospectively evaluated the outcome of autologous and allogeneic SCT for patients with WM using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Forty-six patients receiving autologous and 31 receiving allogeneic SCT were analyzed. The allogeneic SCT group included more patients with advanced disease status at transplant and received more lines of chemotherapy. The cumulative incidences of non-relapse mortality (NRM) at 1 year were 30.0% (95% CI, 14.7–46.9%) in the allogeneic SCT and 0% in the autologous SCT group. The estimated 3-year overall (OS) and progression-free (PFS) survival rates were 84.5% (95% CI, 66.0–93.4%) and 70.8% (95% CI, 53.0–82.9%) in the autologous SCT group, and 52.2% (95% CI, 32.5–68.6%) and 45.0% (95% CI, 26.3–62.0%) in the allogeneic SCT group. No patients died after the first 2 years following allogeneic SCT. In univariate analyses, disease status at SCT was significantly associated with PFS in autologous SCT, and with OS and PFS in allogeneic SCT. These results suggest that both autologous and allogeneic SCT have each potential role in WM. Allogeneic SCT is more curative for WM, but is associated with high NRM.

Original languageEnglish
Pages (from-to)1635-1642
Number of pages8
JournalAnnals of Hematology
Volume99
Issue number7
DOIs
Publication statusPublished - 2020 Jul 1

Keywords

  • Allogeneic
  • Autologous
  • Stem cell transplantation
  • Waldenström’s macroglobulinemia

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Outcome of stem cell transplantation for Waldenström’s macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group'. Together they form a unique fingerprint.

  • Cite this

    Sakurai, M., Mori, T., Uchiyama, H., Ago, H., Iwato, K., Eto, T., Iwasaki, H., Kawata, T., Takamatsu, H., Yamasaki, S., Takanashi, M., Ichinohe, T., Atsuta, Y., & Suzuki, R. (2020). Outcome of stem cell transplantation for Waldenström’s macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group. Annals of Hematology, 99(7), 1635-1642. https://doi.org/10.1007/s00277-020-04078-3